Opdivo is a programmed death receptor-1 (PD-1) blocking antibody. The Food and Drug Administration (FDA) has expanded the approval of Opdivo ® (nivolumab) to include adjuvant treatment of patients 12 ...

The FDA is reviewing Opdivo for stage 2B/2C melanoma, with a decision due by October 13, 2023. CheckMate-76K trial showed Opdivo improved 12-month relapse-free survival rates compared to placebo in ...

Recommendation based on results from the Phase 3 CheckMate -76K trial in patients with stage IIB or IIC melanoma, in which Opdivo demonstrated a statistically significant and clinically meaningful ...

Bristol Myers Squibb’s star Opdivo now can lay claim to an earlier melanoma stage with a new approval that “reinforces the company’s legacy” in treating the cancer type, it said. The FDA blessed the ...

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

Opdivo showed superior long-term efficacy over Yervoy in resected stage 3B-4 melanoma, with improved RFS and DMFS outcomes. Median OS and MSS were not reached, but data favored Opdivo, suggesting a ...

Please provide your email address to receive an email when new articles are posted on . Opdivo (nivolumab) is a programmed cell death protein 1 (PD-1) inhibitor. If approved, it will be the only PD-1 ...

The FDA approved nivolumab as adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, according to the agent’s manufacturer. Nivolumab ...

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...

NEW YORK, May 19 (Reuters) - An experimental Bristol Myers Squibb drug from a new class of immunotherapy used in combination with its big-selling cancer medicine Opdivo significantly extended the time ...

Imneskibart will now enter late-stage trials after the drug offered durable tumour shrinkage in NSCLC, melanoma and other ...